When Should We Start Using Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Diabetic Kidney Disease?
International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Počki - 6(2017), 1, Seite 31-35 |
| Sprache: |
Englisch ; Ukrainisch |
|---|
| Beteiligte Personen: |
D.D. Ivanov [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Angiotensin converting enzyme inhibitors/angiotensin receptor blockers |
|---|
| doi: |
10.22141/2307-1257.6.1.2017.93781 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ015239454 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ015239454 | ||
| 003 | DE-627 | ||
| 005 | 20230501175906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22141/2307-1257.6.1.2017.93781 |2 doi | |
| 035 | |a (DE-627)DOAJ015239454 | ||
| 035 | |a (DE-599)DOAJ43eeca3fcc92466cac7bb246822758c9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a ukr | ||
| 050 | 0 | |a RC870-923 | |
| 100 | 0 | |a D.D. Ivanov |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a When Should We Start Using Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Diabetic Kidney Disease? |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus. | ||
| 650 | 4 | |a diabetic kidney disease | |
| 650 | 4 | |a angiotensin converting enzyme inhibitors/angiotensin receptor blockers | |
| 650 | 4 | |a olmesartan | |
| 650 | 4 | |a international guidelines | |
| 653 | 0 | |a Diseases of the genitourinary system. Urology | |
| 773 | 0 | 8 | |i In |t Počki |d Zaslavsky O.Yu., 2017 |g 6(2017), 1, Seite 31-35 |w (DE-627)DOAJ000141941 |x 23071265 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:1 |g pages:31-35 |
| 856 | 4 | 0 | |u https://doi.org/10.22141/2307-1257.6.1.2017.93781 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/43eeca3fcc92466cac7bb246822758c9 |z kostenfrei |
| 856 | 4 | 0 | |u http://kidneys.zaslavsky.com.ua/article/view/93781 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2307-1257 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2307-1265 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2017 |e 1 |h 31-35 | ||